ENDP Endo International plc

4.78
+0.08  (+2%)
Previous Close 4.7
Open 4.77
Price To Book -1.64
Market Cap 1,083,990,050
Shares 223,103,410
Volume 1,018,816
Short Ratio
Av. Daily Volume 8,661,350
Stock charts supplied by TradingView

NewsSee all news

  1. Endo Launches Generic Version of Afinitor® (everolimus) Tablets in the United States

    DUBLIN, Dec. 10, 2019 /PRNewswire/ -- Endo International plc (NASDAQ:ENDP) today announced that one of its operating companies, Par Pharmaceutical (Par), has received approval for and launched generic Afinitor®

  2. Endo to Participate at Bank of America Merrill Lynch Leveraged Finance Conference

    DUBLIN, Nov. 22, 2019 /PRNewswire/ -- Endo International plc (NASDAQ:ENDP) announced today that members of management will participate in a fireside chat at the Bank of America Merrill Lynch Leveraged Finance Conference

  3. Endo Announces FDA's Acceptance of Original Biologics License Application (BLA) for Collagenase Clostridium Histolyticum (CCH) in Patients with Cellulite

    DUBLIN, Nov. 19, 2019 /PRNewswire/ -- Endo International plc (NASDAQ:ENDP) announced today that the U.S.

  4. Endo Reports Third-Quarter 2019 Financial Results

    - Operating Performance Led by Year-over-Year Double-Digit-Percentage Revenue Growth in Sterile Injectables and in Specialty Products Portfolio of Branded Pharmaceuticals - - Full-Year 2019 Financial Guidance Updated to

  5. Endo Implements CEO Succession Plan

    Paul Campanelli Appointed Chairman of the Board, Will Also Continue as President and Chief Executive Officer Until Successor Appointed; Roger Kimmel Appointed Senior Independent Director DUBLIN, Nov. 4, 2019

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Advisory Committee Meeting March 14, 2017 voted 18 to eight that the benefits of reformulated OPANA ER no longer outweigh its risks.
OPANA ER
Management of pain
Approved October 26, 2015.
BEMA Buprenorphine
Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment for which alternative treatment options are inadequate
CRL issued May 30 2013. Approved March 6 2014.
AVEED (testosterone undecanoate) intramuscular injection
Men diagnosed with hypogonadism
PDUFA date July 6, 2020.
XIAFLEX (collagenase clostridium histolyticum) - RELEASE
Edematous fibrosclerotic panniculopathy (“cellulite”)

Latest News

  1. Endo Launches Generic Version of Afinitor® (everolimus) Tablets in the United States

    DUBLIN, Dec. 10, 2019 /PRNewswire/ -- Endo International plc (NASDAQ:ENDP) today announced that one of its operating companies, Par Pharmaceutical (Par), has received approval for and launched generic Afinitor®

  2. Endo to Participate at Bank of America Merrill Lynch Leveraged Finance Conference

    DUBLIN, Nov. 22, 2019 /PRNewswire/ -- Endo International plc (NASDAQ:ENDP) announced today that members of management will participate in a fireside chat at the Bank of America Merrill Lynch Leveraged Finance Conference

  3. Endo Announces FDA's Acceptance of Original Biologics License Application (BLA) for Collagenase Clostridium Histolyticum (CCH) in Patients with Cellulite

    DUBLIN, Nov. 19, 2019 /PRNewswire/ -- Endo International plc (NASDAQ:ENDP) announced today that the U.S.

  4. Endo Reports Third-Quarter 2019 Financial Results

    - Operating Performance Led by Year-over-Year Double-Digit-Percentage Revenue Growth in Sterile Injectables and in Specialty Products Portfolio of Branded Pharmaceuticals - - Full-Year 2019 Financial Guidance Updated to

  5. Endo Implements CEO Succession Plan

    Paul Campanelli Appointed Chairman of the Board, Will Also Continue as President and Chief Executive Officer Until Successor Appointed; Roger Kimmel Appointed Senior Independent Director DUBLIN, Nov. 4, 2019

  6. Endo Presents New XIAFLEX® (collagenase clostridium histolyticum) Data at the 2019 Fall Meeting of the Sexual Medicine Society of North America (SMSNA)

    DUBLIN, Oct. 25, 2019 /PRNewswire/ -- Endo International plc (NASDAQ:ENDP) today announced that five new studies of XIAFLEX® (collagenase clostridium histolyticum) for the treatment of Peyronie's disease will be

  7. Endo Presents Data on the Use of a Standing MRI for the Evaluation of Cellulite at the American Society for Dermatologic Surgery (ASDS) Annual Meeting

    DUBLIN, Oct. 24, 2019 /PRNewswire/ -- Endo International plc (NASDAQ:ENDP) today announced that it will present data on the use of a standing MRI as compared to prone MRI for the evaluation of cellulite at the upcoming

  8. Movapo® (apomorphine hydrochloride) for Patients with Advanced Parkinson's Disease Now Reimbursed in Most Canadian Provinces

    MONTREAL, Oct. 23, 2019 /CNW/ -- Paladin Labs Inc., a subsidiary of Endo International plc (NASDAQ: ENDP), today announced that patients diagnosed with advanced Parkinson's disease (PD) living in Alberta,

  9. Nevakar Enters into $17.5 Million Product Financing Agreement with H.I.G. Capital Partners for Continued Development of Injectable Products

    BRIDGEWATER, N.J., Oct. 7, 2019 /PRNewswire/ -- Nevakar Inc., a specialty pharmaceutical company developing multiple assets in the ophthalmic and injectable areas, announced today that it has entered into a $17.5 million

  10. Endo to Announce Third-Quarter 2019 Financial Results

    DUBLIN, Oct. 2, 2019 /PRNewswire/ -- Endo International plc (NASDAQ:ENDP) will announce its third-quarter 2019 financial results on November 5, 2019 and members of its senior management team will host a conference call

  11. Endo Announces Successful Culmination of Litigation Regarding FDA Compounding Policy

    DUBLIN, Sept. 30, 2019 /PRNewswire/ -- Endo International plc ("Endo") (NASDAQ:ENDP) today announced the successful culmination of two litigation matters before the U.S. District Court for the District of

  12. Endo Announces Submission of Biologics License Application to FDA for Collagenase Clostridium Histolyticum (CCH) in Patients with Cellulite

    DUBLIN, Sept. 6, 2019 /PRNewswire/ -- Endo International plc (NASDAQ:ENDP) announced today  that the Company has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for

  13. Endo Announces Execution of Final Settlement Agreement and Release Resolving "Track 1" Opioid Cases

    DUBLIN, Sept. 5, 2019 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) today announced that its subsidiaries Endo Pharmaceuticals Inc., Endo Health Solutions Inc., Par Pharmaceutical, Inc. and Par Pharmaceutical

  14. Endo to Present New XIAFLEX® (collagenase clostridium histolyticum) Data at the 2019 American Society for Surgery of the Hand's (ASSH) Annual Meeting

    DUBLIN, Sept. 5, 2019 /PRNewswire/ -- Endo International plc (NASDAQ:ENDP) today announced  that four new studies of XIAFLEX® (collagenase clostridium histolyticum), including real-world data, for the treatment of

  15. Endo Announces Approval of First Generic Orfadin® in U.S.

    DUBLIN, Sept. 4, 2019 /PRNewswire/ -- Endo International plc (NASDAQ:ENDP) today announced that Novitium Pharma, LLC, a partner of Endo's subsidiary Endo Ventures Limited, received approval from the U.S. Food and

  16. Endo Launches Authorized Generic Version of Noxafil® (posaconazole) Delayed-release Tablets in the United States

    DUBLIN, Sept. 3, 2019 /PRNewswire/ -- Endo International plc (NASDAQ:ENDP) announced today that one of its operating companies, Par Pharmaceutical (Par), has begun shipping an authorized generic version of Merck's

  17. Football Legend John Elway Reveals He has Dupuytren's Contracture and Wants Others to Get the "Facts on Hand"

    - Elway joins campaign aimed at encouraging those who think they may have Dupuytren's contracture to seek a diagnosis from a hand specialist and ask about treatments, including nonsurgical options - The common yet